Utilising the patient’s own immune system, CAR-T therapy is typically used to treat leukaemia. Before being returned to the patient and used to treat their ailment, a patient’s blood is usually extracted and sent to a laboratory to be “trained” to combat the cancer cells.

In this instance, the researchers and surgeons used an existing CAR-T therapy variation in conjunction with antibodies to treat three patients with recurrent glioblastoma, and the outcomes were astounding.

Within two days of treatment, one patient’s tumour size shrank by 18.5%, according to a study published in The New England Journal of Medicine. The tumour shrank by a remarkable 60.7% on day 69. The Mass General Brigham said that another patient’s “tumour regressed rapidly.”

An MRI performed five days after the third patient’s therapy